Immunotherapy combo shows promise for rare cancers, but study halted early

NCT ID NCT02938793

Terminated Disease control Sponsor: Prisma Health-Upstate Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tested a combination of two immunotherapy drugs, durvalumab and tremelimumab, in 92 people with advanced rare solid tumors who had no other standard treatment options. The goal was to see if the drugs could shrink tumors and to check for side effects. The study was terminated early, so the full results are not available, but the approach aims to harness the immune system to fight these uncommon cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab and tremelimumab (immunotherapy drugs)
What this could lead to: If it works, this could point toward a new treatment option for people with rare cancers that have few standard therapies.
What could go wrong: This was a small, early-phase study that was terminated, so results are limited. Immunotherapy can cause serious immune-related side effects, and not all rare tumors respond to these drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm Rare Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER RARE DISEASE

Contacts and locations

Locations

Greenville Health System Cancer Institute

Greenville, South Carolina, 29605, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.